Obesity is increasing across Europe, and together with alcohol consumption, is contributing to rising rates of chronic liver diseases. Quantifying the epidemiological and economic burden of obesity and alcohol-related conditions will provide evidence for appropriate interventions and policies to be implemented. This study develops an existing microsimulation model to account for body mass index(BMI) and alcohol as interacting joint risk factors to quantify the burden of liver diseases, stroke, and coronary heart disease(CHD), in France, from 2020 to 2030. The impact of hypothetical scenarios are quantified.
View overview video
Together with Cancer Research UK, we produced a report which looked at the health and economic impact of ever-increasing overweight and obesity rates in the UK. We showed that even a small reduction in obesity prevalence could offset the significant health and economic cost of doing nothing.
A study to systematically review bariatric surgery, weight-management programmes (WMPs) and orlistat pharmacotherapy for adults with severe obesity, and evaluate the feasibility, acceptability, clinical effectiveness and cost-effectiveness of treatment.
The Brief Intervention for Weight Loss Trial enrolled consecutively attending primary care patients who were obese and participants were randomised to physicians opportunistically endorsing, offering, and facilitating a referral to a weight loss programme (support) or recommending weight loss (advice). We use a cohort simulation to predict effects on disease incidence, quality of life, and healthcare costs over 20 years.
This study projected educational inequalities in obesity and smoking prevalence to 2050 based on past obesity and smoking trends by education level. The conclusion was that widening educational inequalities in obesity and smoking prevalence are expected in several European countries if current trends in obesity and smoking prevalence are unaltered. This will impact on inequalities in morbidity and mortality of associated diseases such as diabetes, coronary heart disease and chronic obstructive pulmonary disease.
This project projected the prevalence of obesity across the WHO European region and examined whether the WHO target of halting obesity at 2010 levels by 2025 is achievable. The results were that by 2025, obesity is projected to increase in 44 countries. If present trends continue, 33 of the 53 countries are projected to have an obesity prevalence of 20% or more.
Non-communicable diseases (NCDs) such as cardiovascular disease and stroke are a major public health concern across Latin America. We used our microsimulation model to project BMI and related disease trends to 2050. We tested the extent to which interventions that decrease body mass index (BMI) have an effect upon the number of incidence cases avoided for each disease. Without intervention obesity trends will continue to rise across much of Latin America.
This study used our microsimulation model to project obesity trends and future obesity-related disease for nine countries in the Middle East. We found that high rates of overweight and obesity increased in both men and women in most countries. Obesity is a growing problem in the Middle East which requires government action on the primary prevention of obesity.
In this report we modelled the long-term health impacts of obesity in each US state. The results were used as part of an annual report produced by Trust for America’s Health and sponsored by Robert Woods Johnson Foundation.
In 2016, we helped Cancer Research UK show that a 20% sugar-sweetened beverage tax could stop 3.7 million people from becoming obese by 2025. That’s a 5% decrease in national obesity levels. It would save about £10 million in direct NHS healthcare costs in the year 2025 alone.